More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11 ...

Dr. Dan Thomson shares essential tips for injections, needle selection and syringe maintenance to ensure herd health and carcass quality.

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of ...

Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment -- VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected ...

Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) ...

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...

Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks ...

Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI ® ” (brand name in China: “??? ® ”, ...